November was #lungcancerawarenessmonth, but months passing by shouldn't take away our motivation to find more effective and less toxic treatments for people affected by this condition. These are the first results of #AFM24 in NSCLC, and I feel incredibly proud to work with a team that has this "mantra" in mind (more effective but also less toxic), puts patients first, and wakes up every day willing to abate this disease. #innateimmunity #immunotherapy #oncology #clinicaltrials #clinicalresearch #NSCLC
Following our earlier promising #ASH23 update, we are also pleased to announce positive data for our innate cell engager (ICE®) #AFM24 in combination with the PD-L1 checkpoint inhibitor atezolizumab, in heavily pretreated EGFR-Wildtype Non-Small Cell Lung Cancer (#NSCLC) patients. We are encouraged by these promising results, especially considering that patients in this setting are often left without viable treatment options. We will be hosting a webcast today, December 11 at 1:30 p.m. PST / 4:30 p.m. EST / 10:30 PM CET, to discuss the data in more detail. You can read the full press release at: https://lnkd.in/dJXhGpdk